Radiopharm Theranostics Limited (RADX)
NASDAQ: RADX · Real-Time Price · USD
1.520
-0.490 (-24.38%)
At close: Sep 15, 2026, 4:00 PM EDT
1.575
+0.055 (3.63%)
After-hours: Sep 15, 2026, 7:48 PM EDT

Radiopharm Theranostics Ratios and Metrics

Millions USD. Fiscal year is Jul - Jun.

Total Valuation

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
254734122426
Market Cap Growth
-49.13%36.57%192.24%-50.78%-10.18%-
Enterprise Value
202191084
Last Close Price
1.524.194.64---

Price Ratios

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
PS Ratio
2.654.994.168.935.74-
PB Ratio
1.603.021.210.640.780.61
P/TBV Ratio
-----5.56

EV Ratios

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
EV/Sales Ratio
2.152.301.158.022.04-

Financial Efficiency

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
Net Debt / Equity Ratio
-0.18-0.18-0.68-0.68-0.26-0.43
Net Debt / EBITDA Ratio
0.080.080.900.580.461.59
Net Debt / FCF Ratio
0.080.080.800.810.502.72
Asset Turnover
0.180.180.160.030.08-
Quick Ratio
1.141.142.651.111.223.43
Current Ratio
1.161.162.671.301.233.46
Return on Equity (ROE)
-174.71%-174.71%-109.20%-131.49%-63.78%-96.82%
Return on Assets (ROA)
-44.61%-44.61%-27.70%-30.04%-22.57%-29.86%
Return on Capital Employed (ROCE)
-126.90%-126.90%-49.10%-64.90%-46.30%-26.40%

Yields

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
Earnings Yield
-154.17%-81.90%-73.69%-274.09%-97.15%-79.40%
FCF Yield
-152.08%-78.38%-70.43%-131.34%-65.25%-25.86%
Buyback Yield / Dilution
-48.05%-48.05%-438.49%-26.36%-68.74%-
SEC Filings: 10-K · 10-Q